Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in ...

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

So, the natural question for Spyre Therapeutics (NASDAQ:SYRE) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as ...

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the 'Company” or 'Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody ...

In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Zura Bio. The company’s shares closed yesterday at $1.96. Elevate Your Investing ...

View the latest Spyre Therapeutics Inc. (SYRE) stock price, news, historical charts, analyst ratings and financial information from WSJ.